ABRAXANE FOR INJECTABLE SUSPENSION
BRISTOL-MYERS SQUIBB CANADA
Quick answers
Is there a shortage of ABRAXANE FOR INJECTABLE SUSPENSION in Canada?
No. There is no current shortage of ABRAXANE FOR INJECTABLE SUSPENSION 100MG reported to Health Canada. Stock can still vary from one pharmacy to another.
Other Products Containing the Same Active Ingredient
These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.
Closest Matches
PACLITAXEL POWDER FOR INJECTABLE SUSPENSION NANOPARTICLE, ALBUMIN-BOUND PACLITAXEL
PANACEA BIOTEC PHARMA LIMITED
Other Products
PACLITAXEL FOR INJECTION
BIOLYSE PHARMA CORPORATION
PACLITAXEL INJECTION USP
SANDOZ CANADA INCORPORATED
⚠ Possible Recall or Safety Alert
Health Canada has issued a recall or safety alert matching this product. This match is based on product name similarity and may not be exact — confirm against your specific lot number before taking action.
DIN
02281066
Strength
100MG
Dosage Form
POWDER FOR SUSPENSION
Route
INTRAVENOUS
Compare with another product →
Shortage History
Other Products from BRISTOL-MYERS SQUIBB CANADA
Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.
0.5MG · DIN 02282224
120000000CELLS · DIN 02527138
15MG · DIN 02532573
5MG · DIN 02532557
2.5MG · DIN 02532549
10MG · DIN 02532565
100MG · DIN 00360414
125MG · DIN 02163675
250MG · DIN 02163683
250MG · DIN 02163659
500MG · DIN 02163667
10MG · DIN 01918362